Enalare Therapeutics Inc., a Princeton-based clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, announced that Herm Cukier, president and CEO, will be presenting at BioNJ’s Eleventh Annual BioPartnering Conference which is scheduled virtually for May 18 and 19. In addition, Cukier and Enalare’s Chief Operating Officer, Daniel Motto, will host one-on-one investor and partnership meetings during the two-day event.
Enalare Therapeutics Inc. also announced that it has received an initial contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to support development of the company’s lead product ENA-001.
The funding will be used to advance development of an intramuscular (IM) formulation for ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action and potential broad applications as an agnostic respiratory stimulant. The funding is provided via the BARDA Division of Research, Innovation, and Ventures’ (DRIVe) Repurposing Drugs in Response to Chemical Threats (ReDIRECT) program, in partnership with the BARDA Chemical Medical Countermeasures (MCMs) Program, to support development of therapeutic candidates as MCMs against a range of chemical threats.
“We thank BARDA for their support of ENA-001 and look forward to advancing the development of this novel product for use as an agnostic respiratory stimulant,” said Cukier. “The IM formulation will enable rapid deployment in the community setting, potentially saving lives following exposure to respiratory depressive agents through terrorist attacks, industrial accidents, and other situations including drug overdose.”
To access more business news, visit NJB News Now.Related Articles: